ES2115571T1 - Metodo de tratar enfermedades vasculares progresivas y cronicas. - Google Patents

Metodo de tratar enfermedades vasculares progresivas y cronicas.

Info

Publication number
ES2115571T1
ES2115571T1 ES96917917T ES96917917T ES2115571T1 ES 2115571 T1 ES2115571 T1 ES 2115571T1 ES 96917917 T ES96917917 T ES 96917917T ES 96917917 T ES96917917 T ES 96917917T ES 2115571 T1 ES2115571 T1 ES 2115571T1
Authority
ES
Spain
Prior art keywords
pps
vascular diseases
chronic vascular
treating progressive
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES96917917T
Other languages
English (en)
Other versions
ES2115571T3 (es
Inventor
Gary E Striker
Liliane J Striker
Fred P Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Teva Branded Pharmaceutical Products R&D Inc
Original Assignee
US Department of Health and Human Services
Baker Cummins Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Baker Cummins Pharmaceuticals Inc filed Critical US Department of Health and Human Services
Publication of ES2115571T1 publication Critical patent/ES2115571T1/es
Application granted granted Critical
Publication of ES2115571T3 publication Critical patent/ES2115571T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO PARA EL TRATAMIENTO DE UN PACIENTE MAMIFERO QUE SUFRE UNA ENFERMEDAD VASCULAR PROGRESIVA CRONICA (CPVD) CARACTERIZADA POR CICATRIZACION Y/O FIBROSIS CON EL FIN DE DETENER EL PROGRESO DE LA ENFERMEDAD Y RESOLVER LAS LESIONES DE CICATRIZACION O FIBROTICAS YA FORMADAS. EL METODO CONSISTE EN ADMINISTRAR AL PACIENTE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UNA CANTIDAD EFICAZ DE POLISULFATO DE PENTOSANO (PPS) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. SE PREFIERE LA VIA ORAL DE ADMINISTRACION, CON DOSIS DIARIAS TOTALES DE PPS O DE SAL DE PPS DE ENTRE APROXIMADAMENTE 50 Y 1200 MG POR DIA.
ES96917917T 1995-06-07 1996-06-03 Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. Expired - Lifetime ES2115571T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/478,347 US5643892A (en) 1995-06-07 1995-06-07 Method of treating chronic progressive vascular diseases
PCT/US1996/008367 WO1996040158A1 (en) 1995-06-07 1996-06-03 Method of treating chronic progressive vascular diseases
BR9704114-9A BR9704114A (pt) 1995-06-07 1997-07-28 Processo de tratamento de doenças vasculares progressivas crÈnicas

Publications (2)

Publication Number Publication Date
ES2115571T1 true ES2115571T1 (es) 1998-07-01
ES2115571T3 ES2115571T3 (es) 2003-09-01

Family

ID=25664870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96917917T Expired - Lifetime ES2115571T3 (es) 1995-06-07 1996-06-03 Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.

Country Status (14)

Country Link
US (1) US5643892A (es)
EP (1) EP0809505B1 (es)
AU (1) AU699012B2 (es)
BR (1) BR9704114A (es)
CA (1) CA2210351C (es)
DE (1) DE809505T1 (es)
ES (1) ES2115571T3 (es)
HU (1) HUP9802431A3 (es)
IL (1) IL121217A (es)
NO (1) NO313686B1 (es)
NZ (1) NZ309991A (es)
TW (1) TW434018B (es)
WO (1) WO1996040158A1 (es)
ZA (1) ZA964247B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010005720A1 (en) * 1995-06-07 2001-06-28 U.S.A. As Represented By The Secretary Department Of Health And Human Services Method of treating chronic progressive vascular scarring diseases
US6255295B1 (en) 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
DE19747195A1 (de) * 1997-10-24 1999-04-29 Knoll Ag Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten
WO2001052867A1 (en) * 2000-01-19 2001-07-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
WO2007014155A2 (en) * 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
DK2010220T3 (da) * 2006-04-03 2022-05-23 Ceva Animal Health Pty Ltd Stabiliserede pentosanpolysulfat-(pps)-formuleringer
EP2407174B1 (en) 2009-03-11 2014-05-07 Jellice Co., Ltd. Progression inhibitor or prophylactic agent for atherosclerosis, blood cholesterol level-lowering agent, and functional food or food for specified health uses
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
AU2018437600B2 (en) 2018-08-20 2022-11-17 Reqmed Company, Ltd. Novel pentosan polysulfate sodium preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4966890A (en) * 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
DE3725554A1 (de) * 1987-08-01 1989-02-09 Hoechst Ag Pharmazeutisches kombinationspraeparat sowie dessen herstellung und verwendung
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate

Also Published As

Publication number Publication date
WO1996040158A1 (en) 1996-12-19
EP0809505A4 (en) 1998-07-01
TW434018B (en) 2001-05-16
AU6030096A (en) 1996-12-30
NO313686B1 (no) 2002-11-18
AU699012B2 (en) 1998-11-19
EP0809505A1 (en) 1997-12-03
ZA964247B (en) 1996-12-04
HUP9802431A3 (en) 2001-06-28
ES2115571T3 (es) 2003-09-01
IL121217A (en) 2000-09-28
NO973081D0 (no) 1997-07-02
BR9704114A (pt) 2000-06-06
NZ309991A (en) 2001-03-30
IL121217A0 (en) 1999-10-28
NO973081L (no) 1997-08-27
EP0809505B1 (en) 2003-04-02
CA2210351A1 (en) 1996-12-19
HUP9802431A2 (hu) 1999-02-01
DE809505T1 (de) 1998-05-28
CA2210351C (en) 2003-09-23
US5643892A (en) 1997-07-01

Similar Documents

Publication Publication Date Title
US5801161A (en) Pharmaceutical composition for the intranasal administration of hydroxocobalamin
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
ES2115571T1 (es) Metodo de tratar enfermedades vasculares progresivas y cronicas.
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
IL124977A0 (en) Oral administration of effective amounts of forms of hyaluronic acid
FR2798065B1 (fr) Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
CA2274510A1 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
RU2003125274A (ru) Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
ECSP044986A (es) Composicion farmaceutica que comprende lumiracoxib
US20070292535A1 (en) Strontium compositions and methods of treating arthritic and or osteoporitic conditions
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
US5925625A (en) Pharmaceutical composition for the intranasal administration of hydroxocobalamin
BR9809396A (pt) Método de tratamento de doenças de cicatrização vascular progressivas
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
KR970005283A (ko) 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도
JP2022528481A (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用
AR003957A1 (es) Composicion farmaceutica para tratar un paciente mamifero que sufre una enfermedad vascular cronica progresiva (cpvd)
RU2160102C2 (ru) Применение бензидамина для лечения патологических состояний, вызванных фно
AR032479A1 (es) Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
EP1518554B1 (en) Pharmaceutical composition for the treatment of hyperhomocysteinemia
AR020167A1 (es) Metodo para la prevencion del inicio del asma
Levin et al. Therapeutic trials in acute gouty arthritis